NCT04554056 2022-12-02
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2/3 Completed
Clinical Trials
7 trialsNCT04009941 2020-10-28
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
Peking University
Phase 4 Completed
NCT02944604 2019-01-18
The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy
Peking University
Phase 4 Completed
NCT02005458 2018-07-17
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
Xiamen Amoytop Biotech Co., Ltd.
Phase 2 Completed
NCT02805153 2016-06-20
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02805205 2016-06-20
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02119715 2014-04-22
A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed